NEW ORLEANS – Viamet Pharmaceuticals Inc.'s lead fungal infection fighter, oral VT-1161 (oteseconazole), met the primary endpoint of a phase IIb trial in recurrent yeast infections, besting a placebo in all arms of the trial and laying the groundwork for the company to finalize its phase III protocol ahead of a meeting scheduled shortly with the FDA to discuss next steps, President and CEO Bob Schotzinger told BioWorld Today.